The Joint Clinical Assessment (JCA) is a new cornerstone of the European Union’s efforts to standardize the evaluation of therapies across its member states. As part of the newly implemented Health Technology Assessment (HTA) regulation, this centralized process ensures that medicines are assessed for their relative effectiveness and safety in a consistent manner across all member states. This harmonized system aligns the evaluation of clinical data with the regulatory approval process timeline, creating opportunities to streamline market access while also presenting new challenges. To succeed under the JCA framework, companies must understand its procedural requirements, adapt their evidence generation strategies, and carefully coordinate efforts across internal teams.